GS
RNTX

Gagnon Securities’s Rein Therapeutics RNTX Stock Holding History

Gagnon Securities’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Sell
229,070
-10,450
-4% -$12.6K 0.05% 77
2026
Q1 		$311K Sell
239,520
-700
-0.3% -$868 0.07% 73
2025
Q4 		$279K Buy
240,220
+11,528
+5% +$15.9K 0.06% 76
2025
Q3 		$262K Buy
228,692
+156,947
+219% +$199K 0.05% 80
2025
Q2 		$100K Hold
71,745
– – 0.02% 86
2025
Q1 		$127K Hold
71,745
– – 0.03% 93
2024
Q4 		$165K Sell
71,745
-16
-0% -$48 0.03% 87
2024
Q3 		$254K Buy
71,761
+33,784
+89% +$90.3K 0.05% 78
2024
Q2 		$105K Buy
37,977
+30
+0.1% +$123 0.02% 90
2024
Q1 		$252K Hold
37,947
– – 0.06% 77
2023
Q4 		$116K Buy
+37,947
New +$74K 0.03% 98

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Gagnon Securities's RNTX Position: Q2 2026 in Review

Gagnon Securities reduced its Rein Therapeutics (RNTX) stake by 4.4% in Q2 2026, selling an estimated $12.6K and leaving 229,070 shares worth $238K. The position accounts for 0.05% of the portfolio, ranked #77.

Gagnon Securities first reported a position in RNTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $311K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Gagnon Securities held 229,070 shares of Rein Therapeutics worth $238K as of Q2 2026.
  • Gagnon Securities sold 10,450 Rein Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Rein Therapeutics made up 0.05% of Gagnon Securities's portfolio in Q2 2026, its #77 holding.
  • Gagnon Securities first reported a position in Rein Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Gagnon Securities's Rein Therapeutics position peaked at $311K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Gagnon Securities's 13F filing for Q2 2026, filed 5 Aug 2026.